Home » Healthcare » Pharmaceuticals » Treatment-Resistant Depression (TRD) Treatment Market

Treatment-Resistant Depression (TRD) Treatment Market By Drug Class (Selective serotonin reuptake inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant Inhibitors, Anti-N-methyl-d-aspartate receptor, Others) By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) – Growth, Future Prospects And Competitive Analysis, 2016 – 2028

Price: $4999

Published: | Report ID: 11720 | Report Format : PDF

What are the different treatment options for Treatment-Resistant Depression (TRD)?

Treatment-Resistant Depression is described as depression that does not react or improves after being treated with two different antidepressant classes. Furthermore, it is a difficult clinical problem that is utilised to define the elements that influence serious depression disorders. In addition, in the treatment of treatment-resistant depression, integrated therapeutic techniques such as changing antidepressants, optimising drugs, using a combination of antidepressants, and using physiological therapies are used. Electroconvulsive therapy, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and vagus nerve stimulation are among the somatic therapies employed. Depression is the most prevalent clinical condition associated with mental illnesses.

According to a WHO article named “Depression” released in September 2021, depression is a prevalent disorder globally, affecting an estimated 3.8% of the population, including 5.0% of adults and 5.7% of persons over 60 years. Depression affects around 280 million people globally. It can cause a person to suffer greatly and perform poorly at work, school, and in the family. In the worst-case situation, depression can lead to suicide. Every year, over 700,000 people commit suicide. TRD, on the other hand, has two therapy options: pharmacological and non-pharmacological therapies. Among the pharmacologic therapy options include switching, combination, and potentiation strategies among commonly used antidepressant medications.

TRD is treated with antidepressants such as selective serotonin reuptake inhibitors (SSRIs), non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, Agomelatine, dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, and Tianeptine. Non-pharmacological therapies include electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), and repetitive transcranial magnetic stimulation (rTMS). Furthermore, interpersonal therapy are two additional psychotherapy approaches (IPT) and cognitive-behavioral therapy (CBT).

WTreatment-Resistant Depression (TRD) Treatment Markethat is the Market Size of Treatment-Resistant Depression (TRD) Treatment in terms of value?

The global Treatment-Resistant Depression (TRD) Treatment Market is projected to increase at a significant CAGR of 3.50% in the coming years. In 2021, the global Treatment-Resistant Depression (TRD) Treatment market was valued at USD 1318.5 million and is projected to reach at the value of USD 1620.77 million by 2028. The demand for Treatment-Resistant Depression (TRD) Treatment is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 302.27 million during the forecast period of 2022 and 2028.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

What is the key emerging drugs for Treatment-Resistant Depression (TRD) Treatment?

  • AXS-05: Axsome Therapeutics- AXS-05 is a new NMDA receptor antagonist with multimodal activity that is being studied orally. It is being developed to treat central nervous system (CNS) problems and has a proprietary formulation and dose of dextromethorphan (DM) and bupropion. Axsome Therapeutics’ AXS-05 received Priority Review from the FDA (dextromethorphan-bupropion). The accelerated review framework reduces the review time from a standard 10-month period to just six months after the receipt of the New Drug Application (NDA).
  • VRAYLAR (Cariprazine): AbbVie- Cariprazine is an atypical antipsychotic that is taken once a day. It’s a partial agonist for the central dopamine D3 and D2 receptors that preferentially binds to the D3 receptor. It also acts as a partial agonist on serotonin 5-HT1A receptors and as an antagonist on serotonin 5-HT2A receptors. Cariprazine functions as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors, according to pharmacodynamic investigations.

Interesting Facts about Treatment-Resistant Depression (TRD) Treatment Industry

  • The Treatment-resistant Depression (TRD) market is expected to change in the coming years as a result of increased awareness of the disease, the development of diagnostic techniques, and a favourable regulatory environment for innovative first-in-class curative drugs, all of which are expected to expand the market’s size and allow drug manufacturers to penetrate deeper into the market.
  • North America region had a major share in terms of volume as well as value in the global Treatment-Resistant Depression (TRD) Treatment market in 2021 and is projected to continue its dominance over the forecast period.
  • Several new therapies are being developed to address the limitations of presently licenced drugs. AXS-05 (Axsome Therapeutics), Cariprazine (AbbVie), Esketamine DPI (Celon Pharma), AV-101 (VistaGen Therapeutics), REL 1017 (Relmada Therapeutics, Inc./Syneos Health), and MIJ821 (Novartis Pharmaceuticals) are a few examples.
  • Companies and academics are collaborating to examine problems and identify possibilities that may have an impact on treatment-resistant depression (TRD) research and development. Novel techniques to treating/improving medical conditions are the focus of the medicines in development. Treatment-resistant depression therapies are being developed by major players (TRD). The introduction of new medicines will have a substantial impact on the market for treatment-resistant depression (TRD).

Who are the Top 10 players/companies in the Treatment-Resistant Depression (TRD) Treatment market in term of value?

The key players in the global Treatment-Resistant Depression (TRD) Treatment market in terms of value include AstraZenecaPfizer, Inc., GlaxoSmithKline plc, Eli Lilly and CompanyBristol-Myers Squibb Company, Forest Laboratories, Janssen Pharmaceuticals, Inc., and others. These key players are concentrating on new product developments as well as technological innovation to enhance their production in Treatment-Resistant Depression (TRD) Treatment to gain competitive market share at a global level. For instance, in February 2022, The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) for the adjunctive treatment of major depressive disorder (MDD) in patients who are taking antidepressants. On the other hand, in March 2019, the FDA has approved Jansen Pharmaceuticals, Inc.’s Spravato nasal spray, which is an oral antidepressant intended to treat depression in individuals who have tried different antidepressants but have not found them to be effective.

Who are the Top 10 Countries in the Treatment-Resistant Depression (TRD) Treatment Market?

In the global Treatment-Resistant Depression (TRD) Treatment market, the major countries are US, Canada, China, Japan, Australia, Germany, France, Italy, Spain, and UK. The largest market share is in United States. According to the Anxiety and Depression Association of America (AADA), anxiety disorders are the most frequent mental ailment in the United States, impacting 40 million persons aged 18 and over, or 19.1% of the population, each year. The rise in the prevalence of  TRD, the rise in elderly populations, the rise in chronic diseases, and other similar variables are positively driving market expansion. The prevalence of TRD is highest in the 40-60 age group in the United States. As a result, TRD is regarded as the most neglected public health concern, with a projected prevalence of 2% to 3% for Stage 1 TRD and Stage 2 TRD. The market is being driven by an increase in the length of depression, severity of symptoms, the number of Alzheimer’s cases, diabetics, epilepsy, high blood pressure, high cholesterol, and other clinical illnesses that have a significant impact on the body’s natural functioning. In addition, the industry is growing due to manufacturers’ eagerness for creating new FDA-approved medicines. The esketamine nasal spray was recently approved by the US Food and Drug Administration (USFDA) for the treatment of treatment-resistant depression. Esketamine is a medication that is used as a general anaesthetic and for treatment-resistant depression. It is sold under the brand names Ketanest and others. Esketamine is administered through injection into a vein or nasal spray. Esketamine is a non-competitive N-methyl-D-aspartate receptor antagonist in general.

Which is the Key distribution channel segment in the Treatment-Resistant Depression (TRD) Treatment Market?

The market is divided into three segments based on distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies. With increased patient visits and sales of prescription-based medications for treatment of depressive disorders, primarily MDD, the hospital pharmacy industry has the major share internationally. Increasing Medications Prescriptions in Hospitals to Support Market Growth. The growing patient inclination to purchase products from nearby pharmacies on a frequent basis is driving the expansion of the retail pharmacies industry. However, because of the increasing penetration of online pharmacies in emerging nations, the online pharmacy industry is predicted to grow at a profitable rate over the projection period.

What are the Major Driving Factors for Treatment-Resistant Depression (TRD) Treatment Market?

The rise in the prevalence of depression (TRD), the rise in elderly populations, the rise in chronic diseases, and other similar variables are positively driving market expansion. Furthermore, an increase in the duration of depression, intensity of symptoms, an increase in Alzheimer cases, epilepsy, diabetics, high blood pressure, high cholesterol, and other clinical illnesses that significantly impact the normal functioning of the body are driving market expansion. Furthermore, the manufacturers’ interest in creating new pharmaceuticals through FDA approval is driving market expansion.

What are the Major Restraints for Treatment-Resistant Depression (TRD) Treatment Market?

In the absence of FDA approval for the treatment of TRD, a specific combination of antidepressant medication combined with several therapy causes hazardous drug interaction, adverse drug reaction, and other side effects. The rising cost of therapy may stifle market expansion during the forecast period. One of the major barriers to TRD treatment implementation in emerging and developing nations is a lack of sufficient healthcare infrastructure due to low healthcare investment. Only a few healthcare facilities in developing and developing countries are currently equipped to use it.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Which Region Dominated the World Treatment-Resistant Depression (TRD) Treatment Market?

In 2021, North America dominates the Treatment-Resistant Depression (TRD) Treatment market over the forecast period because of a surge in treatment-resistant depression cases, an increase in the number of diabetic patients, new pharmaceutical approvals, newer treatment choices, and more knowledge about the illness. Increases in the prevalence of depression (TRD), older populations, chronic diseases, and other factors are all driving the market’s expansion. Furthermore, an increase in the duration of depression, the severity of symptoms, the number of Alzheimer’s cases, epilepsy, diabetics, high blood pressure, high cholesterol, and other clinical disorders that have a substantial impact on the body’s natural functioning are driving the market. Furthermore, the sector is expanding as a result of manufacturers’ enthusiasm in developing new FDA-approved therapies. According to a report published by the Centers for Disease Control and Prevention in October 2021 titled “National and State Trends in Anxiety and Depression Severity Scores Among Adults according to statistics from the US Census Bureau Household Pulse Survey, the percentage of US individuals exhibiting symptoms of anxiety and depression disorders increased nationwide from August 2020 to February 2021 during the COVID-19 Pandemic — the United States, 2020–2021. From August to December 2020, the average anxiety severity score climbed by 13%. From August 2020 to February 2021, the percentage of adults experiencing recent anxiety or depression symptoms climbed from 36.4 % to 41.5 %.

Asia Pacific is expected to grow at significant rate owing to an increase in the number of geriatrics, an increase in healthcare awareness, and an increase in government initiatives in the healthcare sector, an increase in depression, and an increase in research activities. According to Statista, almost 2.1 million episodes of depression among older adults were documented in India in 2020. Furthermore, the figure is expected to climb to roughly 5 million cases of depression among elderly adults. As a result, the fast increasing incidences of depression among the global population are increasing demand for depression therapy, which is fuelling global market expansion.

Segmentation of Global Treatment-Resistant Depression (TRD) Treatment Market-

Global Treatment-Resistant Depression (TRD) Treatment Market – By Drug Class 

  • Selective serotonin reuptake inhibitors
  • Monoamine Oxidase Inhibitors
  • Tricyclic Antidepressant Inhibitors
  • Anti-N-methyl-d-aspartate receptor
  • Others

Global Treatment-Resistant Depression (TRD) Treatment Market – By Distribution Channel 

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Treatment-Resistant Depression (TRD) Treatment Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Treatment-Resistant Depression (TRD) Treatment Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Type
3.3.2. Application
3.3.3. Geography
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Types
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis
4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players

5. COVID 19 Impact Analysis
5.1. Global Treatment-Resistant Depression (TRD) Treatment Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply
6. North America
6.1. North America Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Selective serotonin reuptake inhibitors
6.2.3. Monoamine Oxidase Inhibitors
6.2.4. Tricyclic Antidepressant Inhibitors
6.2.5. Anti-N-methyl-d-aspartate receptor
6.2.6. Others
6.3. North America Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Hospital pharmacies
6.3.3. Retail Pharmacies
6.3.4. Online Pharmacies
6.3.5. Others

7. Europe
7.1. Europe Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Ukraine
7.1.7. Spain
7.1.8. Belgium
7.1.9. Netherland
7.1.10. Austria
7.1.11. Sweden
7.1.12. Poland
7.1.13. Denmark
7.1.14. Switzerland
7.1.15. Rest of Europe
7.2. Europe Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Selective serotonin reuptake inhibitors
7.2.3. Monoamine Oxidase Inhibitors
7.2.4. Tricyclic Antidepressant Inhibitors
7.2.5. Anti-N-methyl-d-aspartate receptor
7.2.6. Others
7.3. Europe Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Hospital pharmacies
7.3.3. Retail Pharmacies
7.3.4. Online Pharmacies
7.3.5. Others

8. Asia Pacific
8.1. Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Indonesia
8.1.9. Malaysia
8.1.10. Philippine
8.1.11. Rest of Asia Pacific
8.2. Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Selective serotonin reuptake inhibitors
8.2.3. Monoamine Oxidase Inhibitors
8.2.4. Tricyclic Antidepressant Inhibitors
8.2.5. Anti-N-methyl-d-aspartate receptor
8.2.6. Others
8.3. Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. Hospital pharmacies
8.3.3. Retail Pharmacies
8.3.4. Online Pharmacies
8.3.5. Others

9. Latin America
9.1. Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. Selective serotonin reuptake inhibitors
9.2.3. Monoamine Oxidase Inhibitors
9.2.4. Tricyclic Antidepressant Inhibitors
9.2.5. Anti-N-methyl-d-aspartate receptor
9.2.6. Others
9.3. Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. Hospital pharmacies
9.3.3. Retail Pharmacies
9.3.4. Online Pharmacies
9.3.5. Others

10. Middle East
10.1. Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Selective serotonin reuptake inhibitors
10.2.3. Monoamine Oxidase Inhibitors
10.2.4. Tricyclic Antidepressant Inhibitors
10.2.5. Anti-N-methyl-d-aspartate receptor
10.2.6. Others
10.3. Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. Hospital pharmacies
10.3.3. Retail Pharmacies
10.3.4. Online Pharmacies
10.3.5. Others

11. Africa
11.1. Africa Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Selective serotonin reuptake inhibitors
11.2.3. Monoamine Oxidase Inhibitors
11.2.4. Tricyclic Antidepressant Inhibitors
11.2.5. Anti-N-methyl-d-aspartate receptor
11.2.6. Others
11.3. Africa Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. Hospital pharmacies
11.3.3. Retail Pharmacies
11.3.4. Online Pharmacies
11.3.5. Others

12. Global
12.1. Global Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Selective serotonin reuptake inhibitors
12.1.3. Monoamine Oxidase Inhibitors
12.1.4. Tricyclic Antidepressant Inhibitors
12.1.5. Anti-N-methyl-d-aspartate receptor
12.1.6. Others
12.2. Global Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. Hospital pharmacies
12.2.3. Retail Pharmacies
12.2.4. Online Pharmacies
12.2.5. Others

13. Company Profiles
13.1. AstraZeneca
13.2. Pfizer, Inc.
13.3. GlaxoSmithKline plc
13.4. Eli Lilly and Company
13.5. Bristol-Myers Squibb Company
13.6. Forest Laboratories
13.7. Janssen Pharmaceuticals, Inc.
13.8. Johnson& Johnson
13.9. Axsome Therapeutics
13.10. Alkermes, Allergan/ Gedeon Richter
13.11. Minerva Neurosciences
13.12. Acadia Pharmaceuticals
13.13. Celon Pharma
13.14. Relmada Therapeutics
13.15. Others

List of Figures

FIG. 1 Global Treatment-Resistant Depression (TRD) Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Treatment-Resistant Depression (TRD) Treatment Market Segmentation
FIG. 4 Global Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2019 (US$ Bn)
FIG. 5 Global Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2021 (US$ Bn)
FIG. 6 Global Treatment-Resistant Depression (TRD) Treatment Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Geography, 2021
FIG. 8 Global Market Positioning of Key Treatment-Resistant Depression (TRD) Treatment Market Manufacturers, 2019
FIG. 9 Global Treatment-Resistant Depression (TRD) Treatment Market Value Contribution, By Type, 2021 & 2028 (Value %)
FIG. 10 Global Treatment-Resistant Depression (TRD) Treatment Market, by Selective serotonin reuptake inhibitors, Value, 2016-2028 (US$ Bn)
FIG. 11 Global Treatment-Resistant Depression (TRD) Treatment Market, by Monoamine Oxidase Inhibitors, Value, 2016-2028 (US$ Bn)
FIG. 12 Global Treatment-Resistant Depression (TRD) Treatment Market, by Tricyclic Antidepressant Inhibitors, Value, 2016-2028 (US$ Bn)
FIG. 13 Global Treatment-Resistant Depression (TRD) Treatment Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Treatment-Resistant Depression (TRD) Treatment Market Value Contribution, By Application, 2021 & 2028 (Value %)
FIG. 15 Global Treatment-Resistant Depression (TRD) Treatment Market, by Hospital pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 16 Global Treatment-Resistant Depression (TRD) Treatment Market, by Retail Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Treatment-Resistant Depression (TRD) Treatment Market, by Online Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 18 U.S. Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 19 Rest of North America Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 20 U.K. Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 21 Germany Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 22 France Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 23 Italy Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 24 Spain Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 25 Russia Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 26 BENELUX Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 27 Poland Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 28 Austria Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 29 Rest of Europe Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 30 Japan Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 31 China Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 32 India Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 33 South Korea Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 34 Australia Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 35 Southeast Asia Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 36 Rest of Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 37 Middle East & Africa Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 38 South Africa Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 39 Nigeria Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 40 Egypt Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 41 GCC Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 42 Israel Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 43 Latin America Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 44 Mechanicalzil Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 45 Argentina Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 46 Colombia Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 47 Peru Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)
FIG. 48 Chile Treatment-Resistant Depression (TRD) Treatment Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Treatment-Resistant Depression (TRD) Treatment Market
TABLE 2 Global Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 3 Global Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 4 Global Treatment-Resistant Depression (TRD) Treatment Market, by Geography, 2016-2028 (US$ Bn)
TABLE 5 North America Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 6 North America Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 7 North America Treatment-Resistant Depression (TRD) Treatment Market, by Country, 2016-2028 (US$ Bn)
TABLE 8 Europe Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 9 Europe Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 10 Europe Treatment-Resistant Depression (TRD) Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 11 Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 12 Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 13 Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 14 Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 15 Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 16 Latin America Treatment-Resistant Depression (TRD) Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 17 Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 18 Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 19 Middle East Treatment-Resistant Depression (TRD) Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 20 Africa Treatment-Resistant Depression (TRD) Treatment Market, by Type, 2016-2028 (US$ Bn)
TABLE 21 Africa Treatment-Resistant Depression (TRD) Treatment Market, by Application, 2016-2028 (US$ Bn)
TABLE 22 Africa Treatment-Resistant Depression (TRD) Treatment Market, by Country/Region, 2016-2028 (US$ Bn)

Frequently asked questions 

How does COVID-19 Impact the global Treatment-Resistant Depression (TRD) Treatment market?

The global Treatment-Resistant Depression (TRD) Treatment market is expected to be impacted significantly by COVID-19.

Which is the leading market for Treatment-Resistant Depression (TRD) Treatment?

North America accounted for the highest share in the global Treatment-Resistant Depression (TRD) Treatment market in terms of value.

What are the key drivers for the growth of the Treatment-Resistant Depression (TRD) Treatment market?

The market for Treatment-Resistant Depression (TRD) Treatment has grown primarily as a result of major market drivers such as rising cancer prevalence, increased adoption of personalised medicine to tailor patient treatment on an individual level, and significant external funding for R&D.

Which is the drug class segment in Treatment-Resistant Depression (TRD) Treatment Market by drugs by route of administration?

Selective serotonin reuptake inhibitors segment had a major share in 2021 with more than 40% of the market revenue share.

Which is the major distribution channel segment in Treatment-Resistant Depression (TRD) Treatment Market by molecule type?

Hospital pharmacies segment had a major share in 2021 with more than 30% of the market revenue share.

Nanoparticle Formulation Market

Published:
Report ID: 41106

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN